Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas.

MLA

Raj, Nitya, et al. “Pembrolizumab Alone and Pembrolizumab plus Chemotherapy in Previously Treated, Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas.” British Journal of Cancer, vol. 129, no. 2, Aug. 2023, pp. 291–300. EBSCOhost, https://doi.org/10.1038/s41416-023-02298-8.

APA

Raj, N., Chan, J. A., Wang, S. J., Aggarwal, R. R., Calabrese, S., DeMore, A., Fong, L., Grabowsky, J., Hope, T. A., Kolli, K. P., Mulvey, C. K., Munster, P. N., Perez, K., Punn, S., Reidy-Lagunes, D., Von Fedak, S., Zhang, L., & Bergsland, E. K. (2023). Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas. British Journal of Cancer, 129(2), 291–300. https://doi.org/10.1038/s41416-023-02298-8

Chicago

Raj, Nitya, Jennifer A Chan, Stephanie J Wang, Rahul R Aggarwal, Susan Calabrese, April DeMore, Lawrence Fong, et al. 2023. “Pembrolizumab Alone and Pembrolizumab plus Chemotherapy in Previously Treated, Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas.” British Journal of Cancer 129 (2): 291–300. doi:10.1038/s41416-023-02298-8.